Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus Fulvestrant in HR+ Metastatic Breast Cancer
NCT01797120Phase 2Completed
- Sponsor
- PrECOG
- Start
- May 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in breast cancer, sponsored by PrECOG. Started May 2013; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01797120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01797120.